Ambalal Sarabhai Enterprises shines as its JV gets permission to manufacture COVID-19 test with two target genes

27 Nov 2020 Evaluate

Ambalal Sarabhai Enterprises is currently trading at Rs. 20.80, up by 0.65 points or 3.23% from its previous closing of Rs. 20.15 on the BSE.

The scrip opened at Rs. 21.15 and has touched a high and low of Rs. 21.15 and Rs. 20.80 respectively.

The BSE group 'X' stock of face value Rs. 10 has touched a 52 week high of Rs. 30.95 on 20-Aug-2020 and a 52 week low of Rs. 10.01 on 02-Dec-2019.

Last one week high and low of the scrip stood at Rs. 21.15 and Rs. 18.85 respectively. The current market cap of the company is Rs. 154.42 crore.

The promoters holding in the company stood at 30.76%, while Institutions and Non-Institutions held 0.01% and 69.24% respectively.

CoSara Diagnostics, a Joint Venture (JV) of a subsidiary of Ambalal Sarabhai Enterprises and Co-Diagnostics, Inc, Salt Lake City, Utah, USA got permission to manufacture COVID-19 test with two target genes (RdRP & E) from CDSCO. Like one gene test, this test is also highly specific and sensitive with fast and accurate diagnosis of COVID-19 infection with precise accuracy. This is one more step towards commitment of providing diagnostic kits helpful in early diagnosis, evaluation and management of treatment.

Ambalal Sarabhai Enterprises is engaged in manufacturing and marketing of pharmaceutical products, bulk drugs, industrial chemicals, detergents, toiletries, electronics, engineering products, paper, glass and plastic containers and packaging materials.

Ambalal Sarabhai Ent Share Price

48.03 0.23 (0.48%)
01-Jul-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1517.90
Dr. Reddys Lab 6362.00
Cipla 1478.90
Zydus Lifesciences 1066.95
Lupin 1614.95
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.